Opinion|Videos|September 13, 2024
CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you share your experience with CLL treatment? What factors were most important to you when making treatment decisions?
- How did your care team ensure you were educated about treatment options when it came to selecting treatment?
- How do you approach discussing potential adverse events with patients starting on treatments like? What strategies do you recommend for patients to effectively communicate any side adverse effects or concerns to their care team during treatment?
Advertisement
Related to this article
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Advertisement
Advertisement
Trending on CURE
1
Exercise Gave Me Control. It Didn’t Cure My Cancer
2
Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free
3
A Light-Based Treatment Is Now FDA Approved for a Common Skin Cancer
4
Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer
5